

## Clinical Study Experience Prof. Dr. Tilman Todenhöfer

### Clinical Studies as Principal Investigator (AMG studies)

2021- A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPICS-04) (EudraCT 2020-002964-29)

2021- A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer (EudraCT 2020-000348-77)

2021- A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (EudraCT 2020-002209-25)

2021- Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (EudraCT 2020-002646-16)

2021- A Randomized, Open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy, Phase II, EudraCT 2018-004329-10

2021-

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination mit Docetaxel in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC), CheckMate 7DX, EudraCT No 2019-002030-36

2021-

A Randomized Phase 2 Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Subjects Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) and FGFR Mutations or Fusions, Phase II, EudraCT 2019-002449-39

2020 -

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer, Phase II, EudraCT No (2016-004276-21)

2020 -

Pembrolizumab (MK-3475) combination therapies in mCRPC, KEYNOTE-365, phase Ib-II, EudraCT No. EudraCT2016-002312-41

2019 –

Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650), Phase II, EudraCT: 2016-001928-54

2020-

A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy For Localized Prostate Cancer, EudraCT-Nr. 2019-000951-14

2020-

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641), Phase 3, EudraCT: 2018-004117-40

2020-

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921), Phase 3, EudraCT: 2018-004116-22

2020-

An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations, Phase 1b/2, EudraCT: 2019-000359-15

2020-

Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (CREST). Phase 3, EudraCT: 2019-003375-19

2020-

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment With One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010). Phase 3, EudraCT 2018-004118-16

## **Clinical Studies as Deputy PI & Subinvestigator (AMG studies)**

### **Prostate Cancer**

2010 - 2012

MDV3100 versus placebo in metastatic hormone refractory prostate cancer having progressed after docetaxel treatment, AFFIRM, phase III, EudraCT No 2009-013174-41

2010 - 2013

Docetaxel / Prednisone +/- OGX-011 in firstline chemotherapy in metastatic hormone refractory prostate cancer, SYNERGY, phase III, EudraCT No 2010-021011-16

2011-2013

TAK-700 / Prednisone versus placebo in chemonaive metastatic hormone refractory prostate cancer patients, phase III, EudraCT No 2010-018661-35

# STUDIENPRAXIS UROLOGIE

DR. S. FEYERABEND · PROF. DR. T. TODENHÖFER

2011-2013

TAK-700 / Prednisone versus placebo metastatic hormone refractory prostate cancer patients who have progressed after docetaxel chemotherapy, phase III, EudraCT No 2010-018662-23

2011-2013

Integrinantibody EMD versus placebo in bone metastasized, chemo-naive, hormone refractory prostate cancer patients, phase II, EudraCT No 2010-021529-11

2011-2013

Tasquinimod versus placebo in bone metastasized, chemo-naive, hormone refractory prostate cancer patients, phase III, EudraCT No 2010-021870-12

2011 - 2012

Docetaxel / Prednisone in combination with Lenalidomide versus placebo in firstline chemotherapy in hormone refractory prostate cancer, phase III, EudraCT No 2008-007969-23

2011 - 2013

MDV3100 in hormone in chemo-naive hormone refractory prostate cancer, phase III, EudraCT No 2010-020821-41

2012-2013

Secondlinechemotherapy Cabazitaxel 20 versus 25 mg/m<sup>2</sup> in patients having progressed after docetaxel treatment, PROSELICA, phase III, EudraCT No 2010-022163-35

2012 - 2013

Vaccination with RNAactive versus placebo in chemo-naive hormone refractory prostate cancer, phase IIb, EudraCT No 2011-006314-14

2012 - 2013

Dose titrating study of Pasireotide in chemo-naive, metastasized hormone refractory prostate cancer, phase I, EudraCT No 2010-024399-25

2013-2014

Cabozantinib versus Prednisone in metastatic hormone refractory prostate cancer, COMET-1, phase III, EudraCT No 2012-001834-33

2013-2014

Enzalutamid versus Bicalutamid in metastatic hormone refractory prostate cancer, TERRAIN, phase II, EudraCT No 2010-021868-15

2014- 2017

Abiraterone versus placebo in combination with LH-RH therapy in newly diagnosed high risk, hormone-naive prostate cancer patients, LATITUDE, phase II, EudraCT No 2012-002940-26

2014-2017

Abiraterone with different steroid regimens for preventing symptoms associated with mineralocorticoid excess in asymptomatic, chemotherapy-naive and metastatic CRPC, phase II, EudraCT No 2012-004331-23

2014-2016

Tasquinimod versus placebo as maintenance therapy in metastatic prostate cancer patients without progress after firstline docetaxel containing chemotherapy, phase II, EudraCT No 2012-001038-32

2014-2017

Randomized double-blind study with PROSTVAC-V/F +/- GM-CSF in men with asymptomatic or mildly symptomatic metastatic, castrate-resistant prostate cancer, phase III, EudraCT No 2010-021196-85

2014-

Randomized double-blind study with ARN-509 in men with non-metastatic castration - resistant prostate cancer, SPARTAN, phase III, EudraCT No 2012-004322-24

2014-2017

Open label study with enzalutamide in patients with hormone-refractory prostate cancer having progressed on abiraterone therapy, phase IV, EudraCT No 2013-002271-17

2014-

Randomized double-blind study with DCVAC/PCa in men with metastatic hormonrefractory prostate cancer eligible for 1<sup>st</sup> line chemotherapy, SP005, phase III, EudraCT No 2012-002814-38

2015-

Continued enzalutamide in chemotherapy naive mHRPC patients treated with docetaxel / prednisone having progressed on enzalutamide alone, PRESIDE, phase IIIb, EudraCT No 2013-004711-50

2015-

Randomized cabazitaxel dose individualization and neutropenia prevention trial, CAINTA, phase II, EudraCT No 2013-005504-34

2015-2017

Radium-223 alpha emitter agent in non-intervention safety study in mCRPC population for long-term evaluation, phase IV, EudraCT No 2013-002271-17

2015-

Randomized double-blind study with ODM-201 in patients with non-metastatic, castrate-resistant prostate cancer, phase III, EudraCT No 2013-003820-36

2015-

Randomized, intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study, TIM, EudraCT No 2013-003446-16

2015-2017

Single-arm, open-label, post marketing safety study to evaluate the risk of seizure among subjects with metastatic castration-resistant prostate cancer treated with enzalutamide who are at potential increased risk for seizure, phase IV, UPWARD, EudraCT No 2013-003022-92

2015-2016

Study to evaluate pharmacodynamic, pharmacokinetic and safety of Zoreline 10,8 mg subcutaneous Goserelin-implant (Novalon) in subjects with prostate cancer, phase III, EudraCT No 2013-000799-14

2015-

Randomized double-blind study with JNJ-56021927 versus placebo in combination with Abiraterone in metastatic HPRC in chemotherapy-naive men, ACIS, phase III, EudraCT No 2014-001718-25

2016-

Randomized double-blind study with JNJ-56021927 plus androgen deprivation therapy (ADT) versus ADT in subjects with low volume metastatic, hormone sensitive prostate cancer, TITAN, phase III, EudraCT No 2015-000735-32

2016-

Randomized double-blind study with JNJ-56021927 plus androgen deprivation therapy (ADT) versus ADT in subjects with high risk or locally advanced prostate cancer receiving primary radiation therapy, ATLAS, phase III, EudraCT No 2015-003007-38

2016-

Clinical efficacy of abiraterone acetate while sparing LHRH-therapy in patients with castration-resistant prostate cancer progressing after chemotherapy, SPARE, AP 67/11, phase II, EudraCT No 2012-005717-39

2016

Comparator study in men expressing androgen receptor splice variant-7 mRNA (AR-V7) and metastatic castrate resistant prostate cancer, ARMOR3-SV, phase III, EudraCT 2014-005079-10

2016-2018

Pembrolizumab (MK-3475) in subjects with mCRPC previously treated with chemotherapy, KEYNOTE-199, phase II, EudraCT: 2015-003644-40

2017-

Extension study for subjects with prostate cancer who previously participated in an Enzalutamide clinical study, Phase II, EudraCT No 2016-001694-32

2017-

Randomized study of ODM-201 in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer, ARASENS, Phase III, EudraCT No 2015-002590-38

2017-

Randomized, open-label study of Cabazitaxel versus an androgen receptor (AR)-targeted agent (abiraterone or enzalutamide) in mCRPC patients previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent, CARD, Phase IV, EudraCT No 2014-004676-29

2017-

Randomized double-blind, placebo-controlled study of enzalutamide in men with metastatic hormone-sensitive prostate cancer plus androgen deprivation therapy, ARCHES, Phase III, EudraCT No 2015-003869-28

2017-

Open-label, randomized study to assess the efficacy and safety of Olaparib versus Enzalutamide or Abiraterone Acetate in men with metastatic, castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations, PROFOUND, phase III, EudraCT No

2017-2019

Pembrolizumab (MK-3475) combination therapies in mCRPC, KEYNOTE-365, phase Ib-II, EudraCT No. EudraCT2016-002312-41

2017-

Open label, randomized study to assess the efficacy and safety of Olaparib (Lynparza) versus enzalutamide or Abiraterone Acetate in men with mCRPC who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations, phase III, PROfound, D081DC00007, EudraCT No. 2016-002057-38

2017-2018

Treatment with Abiraterone Acetate for metastasized hormone-refractory prostate cancer: early or late onset of therapy, TIME, phase IV

2017-

Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetate, STAR-V7, EudraCT No. 2016-002735-16

2017 –

A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen, EudraCT Nr. 2016-003092-22

2018-

Open-label study of Rucaparib in patients with metastatic castration-resistant prostate cancer associated with homologous recombination deficiency, TRITON2, CO-338-052, phase II, EudraCT No. 2016-003162-13

2018-

Randomized trial for patients with rapidly progressive mHRPC: abiraterone acetate, prednisolone, LHRH-agonist and denosumab versus abiraterone acetate, dexamethasone, LHRH-agonist and denosumab plus biomodulatory therapy including metronomic low-dose treosulfan plus pioglitazone, Moduprostate01 Study, EudraCT No. 2015-004221-14

2018-

Randomized, open-label study of rucaparib versus physician's choice of therapy for patients with metastatic castration-resistant prostate cancer associated with homologous recombination deficiency, TRITON3, phase III, EudraCT No. 2016-003163-20

2018- 2018

Randomized, placebo-controlled trial testing ipatasertib plus abiraterone plus prednisone relative to placebo plus abiraterone plus prednisone in patients with asymptomatic or mildly symptomatic, previously untreated, metastatic castrate-resistant prostate cancer, CO39303, phase III, EurdraCT No. 2016-004429-17

2019-

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer, Phase II, Cyclone 2, EudraCT No (2016-004276-21)

2019–

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer, Phase III, D081SC00001 EudraCT No 2018-002011-10

2019-

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE), Phase III, EudraCT No 2017-003364-12

2019-

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel (CABASTY). Phase III, EudraCT No 2016-001179-60

2019

Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male subjects with prostate cancer EudraCT2015-001756-30-BG

2019-

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2), Phase III, EudraCT 2017-003295-31

2019-

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010), EudraCT 2018-004118-16

2019-

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921), EudraCT 2018-004116-22

2019-

A multicentre Phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic Castration Resistant Prostate Cancer (mCRPC), suitable for treatment with a taxane, EudraCT 2019-000582-21

2019-

Trial of Nivolumab plus Ipilimumab, Ipilimumab alone, or Cabazitaxel in men with mCRPC, CA209-650, phase II, EudraCT No 2016-001928-54

2020-

Randomized, open-label study of adjuvant Apalutamide or standard of care in subjects with high-risk, localized or locally advanced prostate cancer after radical prostatectomy, ADAM, phase II, EudraCT No 2018-004329-10

2021-

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination mit Docetaxel in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC), CheckMate 7DX, EudraCT No2019-002030-36

2021- A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer (EudraCT 2020-000348-77)

2021- A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer, AMPLITUDE (mCSPC) (EudraCT 2020-002209-25)

2022- A First-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W\_pro1 (BNT112) monotherapy and in combination with cemiplimab in patients with prostate cancer, Pro-Merit, RN5609C00, (EudraCT 2018-004321-86)

2022- A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors, XL092-001, (EudraCT 2020-003569-21)

2022- A Phase 3, Randomized, Double-Blind, Study of TALAZOPARIB with ENZALUTAMIDE versus Placebo with Enzalutamide in men with DDR gene mutated mHSPC, TALAPRO-3, PF-06944076, (EudraCT 2021-000248-23)

2022- A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPitello-281), (EudraCT 2020-000346-33)

## **Painful Pelvis Syndrome**

2012-2013

Randomized double-blind study with ASP3652 in women with painful pelvis syndrome / interstitial cystitis, phase II, EudraCT No 2011-004555-39



2017-

Randomized study of 2 doses of AQX-1125 targeting the SHIP1 pathway in subjects with Interstitial Cystitis / Bladder Pain syndrome followed by a 40-week extension period  
phase III, EudraCT No 2016-000906-12

2017-2019

Randomized, double-blind, placebo-controlled proof of concept study to investigate efficacy, safety, pharmacodynamics and pharmacokinetics of ASP6294 in the treatment of female subjects with bladder pain syndrome / interstitial cystitis, SERENITY, 6294-CL-0101, phase IIa, EudraCT No 2016-004138-12

## **Non-muscle invasive Bladder Cancer**

2012 - 2013

Adjuvant treatment with rec-MGAE - A3 + ASCI versus placebo in patients with advanced, non-metastatic urothelial cancer, phase II, EudraCT No 2010-024355-85

2015 - 2019

The SPIES Non-Muscle-Invasive Bladder Cancer Study - A Multicenter Randomized Controlled Study; A Multicenter International Randomized Controlled Study to Compare the Outcome Using the Storz Professional Image Enhancement System (SPIES) Versus White Light Imaging (WLI) During TURB of Non-Muscle-Invasive Bladder Cancer (NMIBC), NCT02252549

2015-

Randomized, intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study, TIM, EudraCT No 2013-003446-16

2017 - 2019

Marker-gestützte Nachsorge von Patienten mit nicht-muskelinvasiven low/intermediate –risk Harnblasentumore (UroFollow)

2018-

Randomized, open-label study of Durvalumab and Bacillus Calmette-Guerin (BCG) administered as combination therapy versus BCG alone in high-risk, BCG-naive non-muscle-invasive Bladder Cancer Patients, POTOMAC, phase III, EudraCT 2017-002979-26

## **Metastatic / Muscle Invasive Bladder Cancer**

2012 - 2013

Adjuvant treatment with rec-MGAE - A3 + ASCI versus placebo in patients with advanced, non-metastatic urothelial cancer, phase II, EudraCT No 2010-024355-85

2016 - ongoing

A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection, EudraCT No. 2014-005603-25

2016 - 2019

A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma, EudraCT No. 2015-005731-41

2017 - 2019

Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901), EudraCT No 2016-003881-14

2017-

Single-agent multicenter study to evaluate the efficacy and safety of INCB054828 in subjects with metastatic or unresectable urothelial carcinoma harboring FGF/FGFR alterations, phase II, EudraCT No 2016-001321-14

2017 - 2019

An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract, EudraCT No. 2016-002625-11

2018 - 2019

Open-label study of Rucaparib in patients with locally advanced or metastatic urothelial carcinoma, ATLAS, CO-338-085, phase II, EudraCT No 2017-004166-10

2017 - 2019

An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors, EudraCT No 2013-002155-15

2017 - 2019

A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS), EudraCT No. 2015-001112-35

2019-

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations. Phase III, EudraCT No 2017-002932-18

2019-

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10), EudraCT 2018-003636-79

## Renal Cell Carcinoma

2010 - 2013

Adjuvant treatment with Pazopanib versus placebo in advanced renal cell carcinoma, phase II, EudraCT No 2010-020965-26

2011 - 2012

Treatment with Sutent in combination with IMA902 in HLA-A2 positive patients in metastatic renal cell carcinoma, phase III, EudraCT No 2010-022459-45

2012 - 2014

Open-label study evaluating the sequential therapy with sorafenib followed by Pazopanib versus Pazopanib followed by Sorafenib, phase III. EudraCT No 2011-004396-36

2012 – 2014

Open randomized trial evaluating the sequential therapy with Bevacizumab, RAD001 and a tyrosine kinase inhibitor in first line clear cell metastatic renal cell carcinoma, phase II, EudraCT No 2011-005939-78

2012 – 2014

Second to fourth line therapy in metastatic renal cell carcinoma with PD-1 antibody versus Everolimus at progression after first line tyrosine kinase inhibitor therapy, phase II, EudraCT No 2011-005132-26

2016 - 2019

A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426), EudraCT No. 2016-000588-17

2016 - 2019

A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427), EudraCT No. 2016-000589-47

2017 - 2019

A Phase 3, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) In Combination With Axitinib (Inlyta(Registered)) Versus Sunitinib (Sutent(Registered)) Monotherapy In The First-line Treatment Of Patients With Advanced Renal Cell Carcinoma, EudraCT No. 2015-002429-20

2017 - 2019

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564), EudraCT No. 2016-004351-75

2017- 2019

A Randomized Phase II Study With NIVOlumab or Continuation of Therapy as an Early SWITCH Approach in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) and Disease Control After 3 Months of Treatment With a Tyrosine Kinase Inhibitor, EudraCT No 2016-002170-13

2017 -2019

A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Advanced Renal Cell Carcinoma After Prior Therapy, NCT02940639

2017 - 2019

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy, EudraCT No 2016-001881-27

2018 - 2019

A Phase 2, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated and Advanced (Unresectable or Metastatic) Non-clear Cell Renal Cell Carcinoma (nccRCC), EudraCT No. 2016-000706-12

2017-

Double-blind, placebo-controlled trial of Pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy, KEYNOTE-564, phase III, EudraCT No 2016-004351-75

## **Testicular Cancer**

2007 - 2012

Comparison between 1 versus 2 cycles of PEB in high-risk non seminoma germ cell tumors, phase II, EudraCT No

2007 - 2012

Comparison between 1 versus 2 cycles of PEB in high-risk non seminoma germ cell tumors, phase II,

2014 - 2019

Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma, EudraCT No. 2011-005840-87

## **Incontinence**

2010 - 2013

Safety and efficacy of Botox in patients with idiopathic urge incontinence, phase III, EudraCT No

2010 - 2013

Urethral sphincter system in patients with grade III stress incontinence after radical prostatectomy or TUR-P, phase II, EudraCT No

## **Clinical experience MPG studies as subinvestigator since 2010**

Since 2022:

Performance of VENTANA PTEN (SP218) RxDx Assay Using OptiView DAB IHC Detection on the BenchMark ULTRA Instrument for Determining the PTEN Status of Specimens Screened for AstraZeneca Phase III Study of Capivasertib + Abiraterone Treatment for De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) D361BC00001 (CAPItello-281)